Steven M. Larson
YOU?
Author Swipe
View article: Comparison of targeting two antigens (GPA33 versus HER2) for <sup>225</sup>Ac-pretargeted alpha-radioimmunotherapy of colorectal cancer
Comparison of targeting two antigens (GPA33 versus HER2) for <sup>225</sup>Ac-pretargeted alpha-radioimmunotherapy of colorectal cancer Open
Purpose: Curative therapies remain a significant unmet need for advanced human colorectal cancer (CRC). The aim of this study was to establish a 3-step 225Ac-DOTA pretargeted radioimmunotherapy (PRIT) system for human CRC, targeting two in…
View article: Molecular Imaging of Androgen Receptor Expression and Glycolysis as Biomarkers for Clinical Outcome for Metastatic Castration–Resistant Prostate Cancer
Molecular Imaging of Androgen Receptor Expression and Glycolysis as Biomarkers for Clinical Outcome for Metastatic Castration–Resistant Prostate Cancer Open
Purpose Patients with metastatic castration–resistant prostate cancer (mCRPC) with tumors that display disease heterogeneity, including features of androgen receptor (AR)–independence and/or lineage plasticity, have particularly poor outco…
View article: <sup>225</sup> Ac α-Pretargeted Radioimmunotherapy of Human Epidermal Growth Factor Receptor 2–Expressing Breast Cancer
<sup>225</sup> Ac α-Pretargeted Radioimmunotherapy of Human Epidermal Growth Factor Receptor 2–Expressing Breast Cancer Open
Radioimmunotherapy using 225Ac, a highly cytotoxic α-particle emitter, has potential for treating advanced breast cancer, especially human epidermal growth factor receptor 2 (HER2)-positive cases. We use a pretargeted radioimmunotherapy (P…
View article: GPA33-pretargeted radioimmunotherapy with mono- and bivalent DOTA-based Lu-177-labeled radiohaptens in a mouse orthotopic liver xenograft model of metastatic human colorectal cancer
GPA33-pretargeted radioimmunotherapy with mono- and bivalent DOTA-based Lu-177-labeled radiohaptens in a mouse orthotopic liver xenograft model of metastatic human colorectal cancer Open
Rationale: Pretargeted radioimmunotherapy (PRIT), which combines systemic antibody-based targeting with ionizing radiation, is promising for treating liver metastases in patients with colorectal cancer (CRC). Previously, we established a t…
View article: Paired primary-metastasis patient-derived organoids and mouse models identify phenotypic evolution and druggable dependencies of peritoneal metastasis from appendiceal cancer
Paired primary-metastasis patient-derived organoids and mouse models identify phenotypic evolution and druggable dependencies of peritoneal metastasis from appendiceal cancer Open
Summary Peritoneal carcinomatosis is a common yet deadly manifestation of gastrointestinal cancers, with few effective treatments. To identify targetable determinants of peritoneal metastasis, we focused on appendiceal adenocarcinoma (AC),…
View article: IL13Rα2-Targeting Antibodies for Immuno-PET in Solid Malignancies
IL13Rα2-Targeting Antibodies for Immuno-PET in Solid Malignancies Open
Interleukin-13 receptor α-2 (IL13Rα2) is a cell surface receptor frequently expressed in solid malignancies, such as glioblastoma and melanoma, with limited expression in healthy tissue, rendering it an ideal target for noninvasive and spe…
View article: Efficacy of HER2-Targeted Intraperitoneal<sup>225</sup>Ac α-Pretargeted Radioimmunotherapy for Small-Volume Ovarian Peritoneal Carcinomatosis
Efficacy of HER2-Targeted Intraperitoneal<sup>225</sup>Ac α-Pretargeted Radioimmunotherapy for Small-Volume Ovarian Peritoneal Carcinomatosis Open
Epithelial ovarian cancer (EOC) is often asymptomatic and presents clinically in an advanced stage as widespread peritoneal microscopic disease that is generally considered to be surgically incurable. Targeted α-therapy with the α-particle…
View article: The use of single-timepoint images to link administered radioiodine activity (MBq) to a prescribed lesion radiation-absorbed dose (cGy): a regression-based prediction interval tool for the management of well-differentiated thyroid cancer patients
The use of single-timepoint images to link administered radioiodine activity (MBq) to a prescribed lesion radiation-absorbed dose (cGy): a regression-based prediction interval tool for the management of well-differentiated thyroid cancer patients Open
Purpose To introduce a biomarker-based dosimetry method for the rational selection of a treatment activity for patients undergoing radioactive iodine 131 I therapy (RAI) for metastatic differentiated thyroid cancer (mDTC) based on single-t…
View article: Data from Quantitative <i>In Vivo</i> Imaging of the Androgen Receptor Axis Reveals Degree of Prostate Cancer Radiotherapy Response
Data from Quantitative <i>In Vivo</i> Imaging of the Androgen Receptor Axis Reveals Degree of Prostate Cancer Radiotherapy Response Open
Noninvasive biomarkers for androgen receptor (AR) pathway activation are urgently needed to better monitor patient response to prostate cancer therapies. AR is a critical driver and mediator of resistance of prostate cancer but currently a…
View article: Supplementary Figures 1 and 2 from Quantitative <i>In Vivo</i> Imaging of the Androgen Receptor Axis Reveals Degree of Prostate Cancer Radiotherapy Response
Supplementary Figures 1 and 2 from Quantitative <i>In Vivo</i> Imaging of the Androgen Receptor Axis Reveals Degree of Prostate Cancer Radiotherapy Response Open
S1. Hierarchical clustering based on Euclidean distance of RNA-seq data demonstrates separation of EBRT-treated (B1-3) and untreated (C1-3) samples.S2. Multi-dimensional scaling plot of RNA-seq data demonstrates separation of EBRT-treated …
View article: Supplementary Figures 1 and 2 from Quantitative <i>In Vivo</i> Imaging of the Androgen Receptor Axis Reveals Degree of Prostate Cancer Radiotherapy Response
Supplementary Figures 1 and 2 from Quantitative <i>In Vivo</i> Imaging of the Androgen Receptor Axis Reveals Degree of Prostate Cancer Radiotherapy Response Open
S1. Hierarchical clustering based on Euclidean distance of RNA-seq data demonstrates separation of EBRT-treated (B1-3) and untreated (C1-3) samples.S2. Multi-dimensional scaling plot of RNA-seq data demonstrates separation of EBRT-treated …
View article: Supplementary Figure Legends from <i>EGFR</i> and <i>MET</i> Amplifications Determine Response to HER2 Inhibition in <i>ERBB2</i>-Amplified Esophagogastric Cancer
Supplementary Figure Legends from <i>EGFR</i> and <i>MET</i> Amplifications Determine Response to HER2 Inhibition in <i>ERBB2</i>-Amplified Esophagogastric Cancer Open
Supplementary Figure Legends
View article: Figure S2 from <i>EGFR</i> and <i>MET</i> Amplifications Determine Response to HER2 Inhibition in <i>ERBB2</i>-Amplified Esophagogastric Cancer
Figure S2 from <i>EGFR</i> and <i>MET</i> Amplifications Determine Response to HER2 Inhibition in <i>ERBB2</i>-Amplified Esophagogastric Cancer Open
CONSORT diagram
View article: Data from <i>EGFR</i> and <i>MET</i> Amplifications Determine Response to HER2 Inhibition in <i>ERBB2</i>-Amplified Esophagogastric Cancer
Data from <i>EGFR</i> and <i>MET</i> Amplifications Determine Response to HER2 Inhibition in <i>ERBB2</i>-Amplified Esophagogastric Cancer Open
The anti-HER2 antibody trastuzumab is standard care for advanced esophagogastric (EG) cancer with ERBB2 (HER2) amplification or overexpression, but intrinsic and acquired resistance are common. We conducted a phase II study of afatinib, an…
View article: Press Conference from Imaging Androgen Receptor Signaling with a Radiotracer Targeting Free Prostate-Specific Antigen
Press Conference from Imaging Androgen Receptor Signaling with a Radiotracer Targeting Free Prostate-Specific Antigen Open
mp3 file (37.5 MB). "Personalized Medicine: Late-breaking Science from AACR Journals," Saturday, March 31, 2012. Hosted by Lewis C. Cantley, Co-Editor-in-Chief of Cancer Discovery, this press conference held during the AACR Annual Meeting …
View article: Figure S1 from <i>EGFR</i> and <i>MET</i> Amplifications Determine Response to HER2 Inhibition in <i>ERBB2</i>-Amplified Esophagogastric Cancer
Figure S1 from <i>EGFR</i> and <i>MET</i> Amplifications Determine Response to HER2 Inhibition in <i>ERBB2</i>-Amplified Esophagogastric Cancer Open
Additional results for dual probe EGFR and ERBB2 FISH from Patients 9, 30 and 32.
View article: Data Supplement from Preclinical Evaluation of Multistep Targeting of Diasialoganglioside GD2 Using an IgG-scFv Bispecific Antibody with High Affinity for GD2 and DOTA Metal Complex
Data Supplement from Preclinical Evaluation of Multistep Targeting of Diasialoganglioside GD2 Using an IgG-scFv Bispecific Antibody with High Affinity for GD2 and DOTA Metal Complex Open
Supplementary Figure S1. Modeling comparison of two different therapy regimens. Supplementary Figure S2. Positron-emission tomography imaging data for I-124 labeled bispecific antibody in tumor-bearing mice. Supplementary Figure S3. Biodis…
View article: Data from Intraperitoneal Pretargeted Radioimmunotherapy for Colorectal Peritoneal Carcinomatosis
Data from Intraperitoneal Pretargeted Radioimmunotherapy for Colorectal Peritoneal Carcinomatosis Open
Peritoneal carcinomatosis (PC) is considered incurable, and more effective therapies are needed. Herein we test the hypothesis that GPA33-directed intracompartmental pretargeted radioimmunotherapy (PRIT) can cure colorectal peritoneal carc…
View article: Data from Quantitative <i>In Vivo</i> Imaging of the Androgen Receptor Axis Reveals Degree of Prostate Cancer Radiotherapy Response
Data from Quantitative <i>In Vivo</i> Imaging of the Androgen Receptor Axis Reveals Degree of Prostate Cancer Radiotherapy Response Open
Noninvasive biomarkers for androgen receptor (AR) pathway activation are urgently needed to better monitor patient response to prostate cancer therapies. AR is a critical driver and mediator of resistance of prostate cancer but currently a…
View article: Figure S2 from <i>EGFR</i> and <i>MET</i> Amplifications Determine Response to HER2 Inhibition in <i>ERBB2</i>-Amplified Esophagogastric Cancer
Figure S2 from <i>EGFR</i> and <i>MET</i> Amplifications Determine Response to HER2 Inhibition in <i>ERBB2</i>-Amplified Esophagogastric Cancer Open
CONSORT diagram
View article: Data from Imaging Androgen Receptor Signaling with a Radiotracer Targeting Free Prostate-Specific Antigen
Data from Imaging Androgen Receptor Signaling with a Radiotracer Targeting Free Prostate-Specific Antigen Open
Despite intense efforts to develop radiotracers to detect cancers or monitor treatment response, few are widely used as a result of challenges with demonstrating clear clinical use. We reasoned that a radiotracer targeting a validated clin…
View article: Data from Preclinical Evaluation of Multistep Targeting of Diasialoganglioside GD2 Using an IgG-scFv Bispecific Antibody with High Affinity for GD2 and DOTA Metal Complex
Data from Preclinical Evaluation of Multistep Targeting of Diasialoganglioside GD2 Using an IgG-scFv Bispecific Antibody with High Affinity for GD2 and DOTA Metal Complex Open
Bispecific antibodies (BsAb) have proven to be useful targeting vectors for pretargeted radioimmunotherapy (PRIT). We sought to overcome key PRIT limitations such as high renal radiation exposure and immunogenicity (e.g., of streptavidin–a…
View article: Figure S1 from <i>EGFR</i> and <i>MET</i> Amplifications Determine Response to HER2 Inhibition in <i>ERBB2</i>-Amplified Esophagogastric Cancer
Figure S1 from <i>EGFR</i> and <i>MET</i> Amplifications Determine Response to HER2 Inhibition in <i>ERBB2</i>-Amplified Esophagogastric Cancer Open
Additional results for dual probe EGFR and ERBB2 FISH from Patients 9, 30 and 32.
View article: Data from <i>EGFR</i> and <i>MET</i> Amplifications Determine Response to HER2 Inhibition in <i>ERBB2</i>-Amplified Esophagogastric Cancer
Data from <i>EGFR</i> and <i>MET</i> Amplifications Determine Response to HER2 Inhibition in <i>ERBB2</i>-Amplified Esophagogastric Cancer Open
The anti-HER2 antibody trastuzumab is standard care for advanced esophagogastric (EG) cancer with ERBB2 (HER2) amplification or overexpression, but intrinsic and acquired resistance are common. We conducted a phase II study of afatinib, an…
View article: Data Supplement from Preclinical Evaluation of Multistep Targeting of Diasialoganglioside GD2 Using an IgG-scFv Bispecific Antibody with High Affinity for GD2 and DOTA Metal Complex
Data Supplement from Preclinical Evaluation of Multistep Targeting of Diasialoganglioside GD2 Using an IgG-scFv Bispecific Antibody with High Affinity for GD2 and DOTA Metal Complex Open
Supplementary Figure S1. Modeling comparison of two different therapy regimens. Supplementary Figure S2. Positron-emission tomography imaging data for I-124 labeled bispecific antibody in tumor-bearing mice. Supplementary Figure S3. Biodis…
View article: Supplementary Tables S1-S10 from <i>EGFR</i> and <i>MET</i> Amplifications Determine Response to HER2 Inhibition in <i>ERBB2</i>-Amplified Esophagogastric Cancer
Supplementary Tables S1-S10 from <i>EGFR</i> and <i>MET</i> Amplifications Determine Response to HER2 Inhibition in <i>ERBB2</i>-Amplified Esophagogastric Cancer Open
Supplementary Tables S1-S10